Thermo Fisher Scientific agreed to acquire clinical trial data firm Clario for about $8.8 billion, folding a major electronic data capture and endpoint‑management platform into its Laboratory Products and Biopharma Services segment. The transaction aims to integrate Clario’s trial‑endpoint software with Thermo Fisher’s existing CRO and lab services footprint to accelerate digitalization of clinical operations and endpoint adjudication. Company statements say the deal will complement Thermo Fisher’s PPD assets and broaden its ability to deliver bundled trial services. Industry analysts expect the move to tighten the competitive set in trial‑tech consolidation and to push legacy CROs to accelerate digital offerings or pursue M&A. Integration execution and regulatory scrutiny of combined data workflows will be near‑term focal points for sponsors and investors.